Kodiak Sciences is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases.  Our Antibody Biopolymer Conjugate or ABC Platform merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine.  In addition to its lead product candidate, KSI-301, a novel anti-VEGF antibody biopolymer conjugate in clinical development for the treatment of age-related macular degeneration and diabetic retinopathy, Kodiak has leveraged its ABC Platform™ to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF bioconjugate for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy.